Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12238637 | 0.89 | ADORA2A (0.58) | ADORA2ASMN1; SMN2LMNAXBP1HSPA9 | |
| SCHEMBL648497 | 0.80 | NPC1 (0.50) | ADORA2ASMN1; SMN2HTR1AHTR1DL3MBTL1 | |
| SCHEMBL33105 | 0.79 | L3MBTL1 (0.49) | ADORA2ASMN1; SMN2HTR1AHTR1DL3MBTL1 | |
| SCHEMBL11922537 | 0.78 | ADORA2A (0.43) | ADORA2ASMN1; SMN2LMNAXBP1FFAR2 | |
| SCHEMBL8345706 | 0.77 | ADORA2A (0.41) | ADORA2ASMN1; SMN2LMNAXBP1HSPA9 | |
| SCHEMBL27742621 | 0.77 | L3MBTL1 (0.48) | ADORA2ASMN1; SMN2L3MBTL1NPY5R | |
| SCHEMBL12824314 | 0.77 | HSD17B10 (0.44) | SMN1; SMN2HTR1AHTR1DL3MBTL1GAA | |
| SCHEMBL5568640 | 0.77 | HRH3 (0.42) | SMN1; SMN2HTR1AHTR1DL3MBTL1GAA | |
| SCHEMBL19161334 | 0.76 | ADORA2A (0.40) | ADORA2ASMN1; SMN2HTR1AHTR1DL3MBTL1 | |
| SCHEMBL2170934 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| US-11220476-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-20200123100-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2020-04-23 | — | — | US | disclosed |
| US-20190314291-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | MODERNATX, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220476-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | ADORA2A 4396/4885SMN1; SMN2 2883/4885LMNA 1539/4885 |
| US-20200123100-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | ADORA2A 4396/4885SMN1; SMN2 2883/4885LMNA 1539/4885 |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | HMOX1, CD209, HMOX2 | ADORA2A 51/4885SMN1; SMN2 3558/4885LMNA 4039/4885 |
| US-20190314291-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | LCP2, CD14, MYD88 | ADORA2A 1789/4885SMN1; SMN2 2066/4885LMNA 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.